TY - JOUR
KW - Addiction Medicine/methods
KW - Clinical Competence
KW - Humans
KW - Professional-Patient Relations
KW - Substance Abuse Detection/methods
KW - Substance-Related Disorders/diagnosis/therapy
AU - M. Jarvis
AU - J. Williams
AU - M. Hurford
AU - D. Lindsay
AU - P. Lincoln
AU - L. Giles
AU - P. Luongo
AU - T. Safarian
A1 - 
AB - : Biological drug testing is a tool that provides information about an individual's recent substance use. Like any tool, its value depends on using it correctly; that is, on selecting the right test for the right person at the right time. This document is intended to clarify appropriate clinical use of drug testing in addiction medicine and aid providers in their decisions about drug testing for the identification, diagnosis, treatment, and recovery of patients with, or at risk for, addiction. The RAND Corporation (RAND)/University of California, Los Angeles (UCLA) Appropriateness Method (RAM) process for combining scientific evidence with the collective judgment of experts was used to identify appropriate clinical practices and highlight areas where research is needed. Although consensus panels and expert groups have offered guidance on the use of drug testing for patients with addiction, very few addressed considerations for patients across settings and in different levels of care. This document will focus primarily on patients in addiction treatment and recovery, where drug testing is used to assess patients for a substance use disorder, monitor the effectiveness of a treatment plan, and support recovery. Inasmuch as the scope includes the recognition of addiction, which often occurs in general healthcare settings, selected special populations at risk for addiction visiting these settings are briefly included.
BT - Journal of addiction medicine
C5 - Opioids & Substance Use
CP - 3
CY - United States
DO - 10.1097/ADM.0000000000000323
IS - 3
JF - Journal of addiction medicine
N2 - : Biological drug testing is a tool that provides information about an individual's recent substance use. Like any tool, its value depends on using it correctly; that is, on selecting the right test for the right person at the right time. This document is intended to clarify appropriate clinical use of drug testing in addiction medicine and aid providers in their decisions about drug testing for the identification, diagnosis, treatment, and recovery of patients with, or at risk for, addiction. The RAND Corporation (RAND)/University of California, Los Angeles (UCLA) Appropriateness Method (RAM) process for combining scientific evidence with the collective judgment of experts was used to identify appropriate clinical practices and highlight areas where research is needed. Although consensus panels and expert groups have offered guidance on the use of drug testing for patients with addiction, very few addressed considerations for patients across settings and in different levels of care. This document will focus primarily on patients in addiction treatment and recovery, where drug testing is used to assess patients for a substance use disorder, monitor the effectiveness of a treatment plan, and support recovery. Inasmuch as the scope includes the recognition of addiction, which often occurs in general healthcare settings, selected special populations at risk for addiction visiting these settings are briefly included.
PP - United States
PY - 2017
SN - 1935-3227; 1932-0620
SP - 163
EP - 173
EP - 
T1 - Appropriate Use of Drug Testing in Clinical Addiction Medicine
T2 - Journal of addiction medicine
TI - Appropriate Use of Drug Testing in Clinical Addiction Medicine
U1 - Opioids & Substance Use
U2 - 28557958
U3 - 10.1097/ADM.0000000000000323
VL - 11
VO - 1935-3227; 1932-0620
Y1 - 2017
ER -